O011 - ORAL DHA SUPPLEMENTATION MODULATES PLASMA LEVELS OF RESOLVINS D1 AND D2 IN NEWLY DIAGNOSED BREAST CANCER PATIENTS

O011

ORAL DHA SUPPLEMENTATION MODULATES PLASMA LEVELS OF RESOLVINS D1 AND D2 IN NEWLY DIAGNOSED BREAST CANCER PATIENTS

G. Imbimbo^1,*, C. Gallicchio¹, G. Salerno², L. Lionetto², A. De Luca³, M. Simmaco², M. I. Amabile³, M. Muscaritoli¹, A. Molfino¹

¹Department of Translational and Precision Medicine , ²Analytical Laboratory Unit, Department NESMOS, ³Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy

Rationale: Resolvin D1 (RvD1) and D2 (RvD2)—derived from docosahexaenoic acid (DHA)—have shown significant anti-inflammatory and anticancer effects. This study aimed to assess the impact of oral DHA supplementation on plasma levels of RvD1 and RvD2 in breast cancer patients compared to healthy controls, with additional analysis based on disease presentation (sporadic, familial, BRCA1/2-mutated) and immunohistochemical tumor characteristics.

Methods: This is a single-center, interventional, controlled study conducted in women with a new diagnosis of breast cancer and women with benign breast disease, serving as controls. Participants consumed DHA (2 g/day) as algal oil syrup for 10 consecutive days. Plasma RvD1 and RvD2 levels were measured at baseline (T0) and after supplementation (T1) by ELISA kits.

Results: At baseline, breast cancer patients exhibited higher plasma RvD1 levels compared to controls (median 21.3 vs. 7.3 pg/mL, p<0.05), with no significant difference in RvD2. Following DHA supplementation, RvD1 and RvD2 significantly increased in BRCA1/2-mutated patients (+185.8% and +101.2%, p<0.05). Conversely, the familial breast cancer group showed a significant decrease in RvD1 (p=0.015). Patients with low Ki67 expression showed greater increase overtime of RvD2 levels compared to those with high Ki67 expression (p=0.046).

Conclusion: DHA supplementation influenced plasma resolvin levels in breast cancer patients, with a significant increase observed in those carrying BRCA1/2 mutations, suggesting an enhanced pro-resolving inflammatory response in this setting. In contrast, the decrease in resolvin D1 levels within the familial group may reflect a dysregulated resolution mechanism. These results support the potential role of resolvins as biomarkers for inflammation resolution and as emerging therapeutic targets in breast cancer management.

Disclosure of Interest: None declared